Ken James

THE KRATOM WARS: ROUND TWO — FOLLOW THE MONEY. For nearly three years, the traditional kratom industry fought a battle against companies flooding the market with highly concentrated 7-OH and synthetic opioid analogs. They said it was about money. We said it was about CONSUMER SAFETY. In 2026, federal regulators took historic action against potent synthetic compounds and moved toward scientifically distinguishing enhanced 7-OH products from traditional botanical kratom. That was a victory for science, responsible manufacturing, and consumer protection. But now another battle is taking shape. This time, the opposition includes voices from the pharmaceutical and addiction-treatment establishment. Consider the economics. Manufacturers of opioid-dependence medications generate revenue from prescription treatments. Addiction-treatment networks generate revenue from counseling, rehabilitation, and medication-assisted treatment. Traditional kratom represents an alternative some consumers already choose. So who benefits financially if traditional kratom disappears? Federal campaign-finance records confirm that major behavioral-health corporations have contributed money to lawmakers across both political parties. Lobbying disclosures also document substantial spending to influence opioid-treatment policy. Those financial relationships deserve scrutiny, particularly when lawmakers advocate eliminating botanical kratom rather than establishing enforceable safety standards. Let me be clear: campaign contributions alone don’t prove corruption, and financial interests alone don’t establish a coordinated conspiracy. But the American public deserves answers. Who is funding the organizations demanding kratom prohibition? Which pharmaceutical companies and addiction-treatment businesses are financially connected to those campaigns? And why should responsibly manufactured botanical products be treated the same as concentrated synthetic opioids? The first battle was about protecting consumers from dangerous products. The next battle must be about protecting consumers through science, transparency, and accountability—not protecting anyone’s market share. We didn’t spend three years fighting concentrated 7-OH just to abandon the distinction between traditional kratom and synthetic opioid products. FOLLOW THE SCIENCE. FOLLOW THE MONEY. PROTECT THE CONSUMER. #Kratom #ConsumerSafety #FollowTheMoney #BotanicalScience #FDA #Transparency #KratomRegulation